Thrivent Financial for Lutherans’s GenMark Diagnostics, Inc GNMK Stock Holding History

Thrivent Financial for Lutherans’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-410,483	Closed	-$2.49M	–	2280
2019 Q3	$2.49M	Sell	410,483 -56,635	-12%	-$353K	0.01%	893
2019 Q2	$3.03M	Buy	467,118 +169	+0%	+$1.19K	0.01%	818
2019 Q1	$3.31M	Buy	466,949 +212	+0%	+$1.4K	0.01%	784
2018 Q4	$2.27M	Sell	466,737 -68,729	-13%	-$358K	0.01%	794
2018 Q3	$3.94M	Sell	535,466 -64,543	-11%	-$474K	0.01%	707
2018 Q2	$3.83M	Buy	600,009 +3,247	+0.5%	+$21.5K	0.01%	718
2018 Q1	$3.25M	Buy	596,762 +7,792	+1%	+$38.7K	0.01%	749
2017 Q4	$2.46M	Hold	588,970	–	–	0.01%	842
2017 Q3	$5.67M	Buy	588,970 +62,110	+12%	+$645K	0.02%	573
2017 Q2	$6.23M	Buy	526,860 +208,000	+65%	+$2.66M	0.03%	512
2017 Q1	$4.09M	Buy	318,860 +21,210	+7%	+$255K	0.02%	636
2016 Q4	$3.64M	Buy	+297,650	New	+$3.53M	0.02%	679

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Thrivent Financial for Lutherans's GNMK Position: Q4 2019 in Review

Thrivent Financial for Lutherans sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2019, closing a stake of 410,483 shares — an estimated $2.49M sold.

Thrivent Financial for Lutherans first reported a position in GNMK in Q4 2016 and held it in 12 quarters. The position peaked at $6.23M in Q2 2017. 111 funds tracked by Wall St. Rank hold GNMK as of Q4 2019.

Thrivent Financial for Lutherans reported no remaining GenMark Diagnostics, Inc position as of Q4 2019 after selling out during the quarter.
Thrivent Financial for Lutherans sold 410,483 GenMark Diagnostics, Inc shares in Q4 2019, an estimated $2.49M.
Thrivent Financial for Lutherans first reported a position in GenMark Diagnostics, Inc in Q4 2016 and held it in 12 quarters.
Thrivent Financial for Lutherans's GenMark Diagnostics, Inc position peaked at $6.23M in Q2 2017.
111 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2019.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2019, filed 13 Feb 2020.